- Home
- STNG vs IBRX Comparison
STNG vs IBRX Comparison
Compare STNG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STNG
- IBRX
- Stock Information
- Founded
- STNG 2009
- IBRX 2014
- Country
- STNG Monaco
- IBRX United States
- Employees
- STNG N/A
- IBRX N/A
- Industry
- STNG Marine Transportation
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STNG Consumer Discretionary
- IBRX Health Care
- Exchange
- STNG Nasdaq
- IBRX Nasdaq
- Market Cap
- STNG 2.7B
- IBRX 2.4B
- IPO Year
- STNG 2010
- IBRX N/A
- Fundamental
- Price
- STNG $47.49
- IBRX $2.62
- Analyst Decision
- STNG Buy
- IBRX Buy
- Analyst Count
- STNG 5
- IBRX 2
- Target Price
- STNG $75.40
- IBRX $17.38
- AVG Volume (30 Days)
- STNG 832.7K
- IBRX 6.1M
- Earning Date
- STNG 02-12-2025
- IBRX 11-12-2024
- Dividend Yield
- STNG 3.37%
- IBRX N/A
- EPS Growth
- STNG 14.72
- IBRX N/A
- EPS
- STNG 13.96
- IBRX N/A
- Revenue
- STNG $1,376,295,000.00
- IBRX $7,332,000.00
- Revenue This Year
- STNG N/A
- IBRX $2,572.99
- Revenue Next Year
- STNG N/A
- IBRX $747.59
- P/E Ratio
- STNG $3.40
- IBRX N/A
- Revenue Growth
- STNG N/A
- IBRX 1218.71
- 52 Week Low
- STNG $45.94
- IBRX $2.61
- 52 Week High
- STNG $84.67
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- STNG 32.69
- IBRX 28.04
- Support Level
- STNG $45.94
- IBRX $2.61
- Resistance Level
- STNG $48.76
- IBRX $3.18
- Average True Range (ATR)
- STNG 1.46
- IBRX 0.28
- MACD
- STNG 0.26
- IBRX -0.20
- Stochastic Oscillator
- STNG 24.37
- IBRX 0.40
About STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owns, lease finances or bareboat charters in hundred ten product tankers namely thirty nine LR2 tankers, fifty seven MR tankers and forteeen Handymax tankers. The company's fleet of tankers is the largest, most eco-friendly and newest fleet on the water hauling clean petroleum products. They provide seaborne transportation of crude oil and refined petroleum products worldwide. The company generates majority of its revenue from MR vessel.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.